• Cyprotex is a UK incorporated entity whose main operations are based in the UK and its shares trade on the AIM platform of the LSE.
• The number of Cyprotex Securities in issue, as at 31st December 2007, is 138,647,988 ordinary shares of 0.1p each. None of those shares are held in Treasury and all shares, excluding those held by directors, Bank of Scotland and Intercapital Private Group Ltd (which represent 36.8% of the issued share capital of the company) are in public hands (as defined by the AIM rules).
• There are no restrictions on the transfer of Cyprotex shares.
• As of 28th March 2008, the following held shareholdings in excess of 3%:
  • Bank of Scotland (28,645,546 - 20.67%)
  • Intercapital Private Group Ltd (21,024,465 - 15.17%)
  • D. Leahy (10,419,100 - 7.52%)
  • R. Long (7,200,00 - 5.20%)
  • Artemis Fund Managers (4,470,000 - 3.23%)
  • BNP Paribas (4,222,000 - 3.05%)
• As of 28th March 2008, the directorate shareholdings were:
  • R. Morrision Atwater (1,835,000)
  • R. B. Gibbs (50,000)
  • N. Sofronis (40,000)
  • D. Evans (25,000)

The above disclosures are in compliance with AIM Rule 26